Wed, Nov 26, 2014, 5:02 AM EST - U.S. Markets open in 4 hrs 28 mins

Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

jetmanbash 237 posts  |  Last Activity: 8 hours ago Member since: Dec 29, 2004
  • AMERICAN HEART ASSOCIATION’S
    SCIENTIFIC SESSIONS 2014
    NOVEMBER 16-19, 2014
    CHICAGO, IL
    Session Type Poster Presentation
    Session Title Session APS.202.03 - Familial Hypercholesterolemia and
    Other Lipid Disorders
    Date Tuesday, November 18, 2014
    Time 9:30 a.m. – 11:o0 a.m. CT
    Location South Hall A2 - Core 2
    Abstract Number 16531
    Title DECREASED CARDIOVASCULAR EVENTS IN FAMILIAL
    HYPERCHOLESTEROLEMIC PATIENTS TREATED WITH
    MIPOMERSEN, AN ANTISENSE INHIBITOR OF
    APOLIPOPROTEIN B TRANSLATION
    Bart Duell, Oregon Health and Science Univ, Portland, OR; Raul D. Santos, Univ
    of Sao Paulo Medical Sch Hosp, Sao Paulo, Brazil; Mary P. McGowan, Asif
    Mahmood, Genzyme Corp – a Sanofi company, Cambridge, MD; Brenda F.
    Baker, Richard S. Geary, Walter Singleton, Isis Pharmaceuticals, Inc, Carlsbad,
    CA; John J.P. Kastelein, Academic Medical Ctr, Univ of Amsterdam, Amsterdam,
    Netherlands
    \2
    Session Type Poster Presentation
    Session Title Session APS.202.01 - Treatment of Hyperlipidemia
    Date Monday, November 17, 2014
    Time 9:30 a.m. – 11:o0 a.m. CT
    Location South Hall A2 - Core 2
    Abstract Number 16993
    Title AN ANTISENSE INHIBITOR OF APOLIPOPROTEIN C-III
    SIGNIFICANTLY DECREASES NONESTERIFIED FATTY ACID
    LEVELS IN SEVERE HYPERTRIGLYCERIDEMIC PATIENTS
    Veronica Alexander, Isis Pharmaceuticals, Carlsbad, CA; Diane Brisson, Dept of
    Med Univ de Montréal and ECOGENE–21, Chicoutimi, QC, Canada; JoAnn Flaim,
    Steve Hughes, Walter Singleton, Richard Geary, Isis Pharmaceuticals, Carlsbad,
    CA; Daniel Gaudet, Dept of Med Univ de Montréal and ECOGENE–21, Chicoutimi,
    QC, Canada
    Session Type Poster Presentation
    Session Title Session APS.702.02 - Mechanisms of Atherosclerosis V
    Date Monday, November 17, 2014
    Time 3:00 p.m. – 4:30 p.m. CT
    Location South Hall A2 - Core 7
    Abstract Number 11747
    Title THE TMAO GENERATING ENZYME FLAVIN MONOOXYGENASE
    3 (FMO3) IS A NOVEL REGULATOR OF CHOLESTEROL
    BALANCE
    Manya Warrier, Stephanie Marshall, Cleveland Clinic, Cleveland, OH; Allison
    McDaniel, Wake Forest

  • jetmanbash jetmanbash Nov 7, 2014 1:31 AM Flag

    Light the fuse for corporate blow-up of vicl. Coming soon, maybe not December, but maybe the pink sheets by March, and the big vaccination in the sky by next year this time. Can hardly wait. t

  • Reply to

    Drop outs

    by rickyriccardo Nov 4, 2014 8:15 AM
    jetmanbash jetmanbash Nov 6, 2014 8:39 AM Flag

    Did you listen to the CC? Can't waste my time on this, wish you the very best luck!! t

  • Reply to

    Drop outs

    by rickyriccardo Nov 4, 2014 8:15 AM
    jetmanbash jetmanbash Nov 6, 2014 8:21 AM Flag

    Was this the equivalent of a lover on the rebound? Now the company has little cash left and a new drug launch to do. The side-effects are even scarier than juxta. And can you say, shelf offering?

  • Reply to

    Drop outs

    by rickyriccardo Nov 4, 2014 8:15 AM
    jetmanbash jetmanbash Nov 6, 2014 8:02 AM Flag

    I would urge you to listen to the CC. Your number(s) are incorrect. In any case your company has bought another drug from AZN for $325 million so maybe expect another shelf offering of stock. t

  • As the market hits all time highs vicl is only 15 cents above its yearly low. Companies like KITE are going to leave it in the dust. t

  • Reply to

    Drop outs

    by rickyriccardo Nov 4, 2014 8:15 AM
    jetmanbash jetmanbash Nov 5, 2014 11:27 PM Flag

    That is a good idea, something like those diet food companies. That would only be about $350 month for each patient which isn't too much considering the price of the med. But IMO that still wouldn't work. And the other issue that no one wants to talk about is the liver enzyme elevations. Part of why Mr. Beer changed the way they reported the data is so that people couldn't see how much drug people were on in regards to dosing. Most of them were on much lower doses than what the average person was in their study. So it becomes push-me pull-me. You raise the dose and the liver enzymes go up. You lower the dose after holding the drug and the liver enzymes go down, but your LDL goes up. I suspect, like Metformin, once you hit a certain dose no matter what you do you get diarrhea. Problem is then the drug does not match its study's rate of efficacy and you lose cost-effectiveness. The drug has been out as long as the competitor and I wonder where the CV risk reduction is. The competitor reported an eight fold reduction during the time frame since release in CV events. With an average of 5 to 10mg being used I doubt that juxta will be able to match those results. t

  • Reply to

    Drop outs

    by rickyriccardo Nov 4, 2014 8:15 AM
    jetmanbash jetmanbash Nov 5, 2014 11:20 PM Flag

    You are losing credibility. The insurance rates were not added into the drop out rates. The drop out rates are the drop out rates. If you listen to the CC JS the analyst who loved the stock really took Mr. Beer out to the wood shed and let him have it in regards to to what Mr. Beer promised. He said that if the drop out rate exceeded 20% he was going to take so and so out in back and shoot him.....not a good thing for Mr. Beer to say previously in just kidding based on what is going on about him at this time. But in any case you are not facing reality. They only had 23 patients complete a study from which they obtained a lot of bravado. Those patients were watched like a hawk. Their diet and oral med intake watched under almost Putin conditions. In the real world.....and this where Mr. Beer has a distinct weakness as he is not a practicing physician so he wouldn't really know how people are in general in regards to adherence to diabetic diets, CHF diets etc. Despite their throwing a tremendous amount of resources.....limited ones I might add, with their increased nurses to monitor everything they couldn't approach their study results in the real world. A phenomena that is often seen after a drug gets approved. Mr. Beer's head is going to be spinning. He is almost a National Enquirer superstar. He has possibly depositions coming in the divorce case because once you are mentioned lawyers can do anything and they could be calling him in for depositions. He has first generation lawsuits from the first time there was a big drop. He has now second generation lawsuits from the second drop....I've never seen that before. He has Brazil problems, and I suspect there will be further bribing problems in other places around the world. He will have BOD problems. Glad I'm not him. t

  • jetmanbash jetmanbash Nov 2, 2014 4:10 PM Flag

    I agree, but I would be careful in regards to shorting this. All it would take would be for an announcement like SNY is going to buy them out and you could see a quick five points to the upside. t

  • jetmanbash jetmanbash Nov 2, 2014 9:17 AM Flag

    Thank you, t

  • If so it would be nice to know the exact time and if we can get access to it....If that isn't possible a copy of the transciprt would be nice. TIA, t

  • Reply to

    Don't allow the BOD

    by tnorman61 Nov 1, 2014 4:45 PM
    jetmanbash jetmanbash Nov 1, 2014 7:39 PM Flag

    I think I'd just let the building crumble in on itself. Mr. Beer is hoping for the PCSK9 inhibitors to raise awareness for HoF and thus increase eligible patients for juxta. The ratio of patients leaving juxta for the PCSK9 inhibitors to those going on juxta will be 5:1 going away from juxta. Only the really worst patients with absolutely no LDL receptors will not at least to a certain degree be helped by the PCSK9 inhibitors. The price advantage too will dictate that insurance carriers will make you show that the patient failed on a PCSK9 inhibitor first. Also, there has never been any release of the average dose of juxta used in any of the patients. Pharm reps will tell you that most patients are on 5 or 10 mg and that's all they need. I think the real truth is that patients have a hard time taking anything higher than that. That may be part of why Mr. Beer about six months ago made the data much more cryptic in regards to giving out information on juxta. t

  • jetmanbash jetmanbash Nov 1, 2014 1:21 PM Flag

    Someone is your master because you keep doing the same thing for free. t

  • jetmanbash jetmanbash Nov 1, 2014 3:01 AM Flag

    vcal will be BK very soon. The sooner the better. t

  • Reply to

    Vical's in the lead by years !

    by macrosanuff Oct 7, 2014 10:36 AM
    jetmanbash jetmanbash Nov 1, 2014 2:59 AM Flag

    You should scram, you are on the wrong board and you don't know xxxxx about xxxxxx. t

  • jetmanbash jetmanbash Nov 1, 2014 2:59 AM Flag

    vicl is a loser company. Any neutral person will see that. Any person who is really into vaccinations will see that vicl is one of the worst in the field. The company is being passed up by better biotechs with better technology in that field. Look at KITE, BLUE, NVAX for much better companies. vicl is a zero company, and will always be a zero company. t

  • jetmanbash jetmanbash Nov 1, 2014 2:53 AM Flag

    You are one uninformed snoopy m'er who dosen't S about S. But keep it up, you will just look more stupid as time goes on. t

  • jetmanbash jetmanbash Nov 1, 2014 2:51 AM Flag

    A non-sensical statement for a dildxxx that won't impress any body. I know you will keep it up because that is your life's work. So God bless you, but you will continue to look like a fool as time goes on. t

  • Reply to

    Q3 CC NEXT FRIDAY NOV 7TH

    by coldpizza22 Oct 31, 2014 7:33 AM
    jetmanbash jetmanbash Nov 1, 2014 2:49 AM Flag

    You come over to the ISIS board with an agenda and you call regular ISIS investors jerks. You are you stupid XXXXXXXX. You are going to continue to be wrong , jealous, and a jerk yourself. Your stupid vicl is destined to be like a third world country. You can continue to come over here but no one is going to listen to you because you don't know xxxxxxxx about ISIS and you keep promoting this dog xxxxxx stock vicl. But I guess that is how it is going to be. You will continue to look out of touch, and a xxxxxxxx. But that is up to you. You have a very poor track record. t

  • jetmanbash jetmanbash Nov 1, 2014 2:38 AM Flag

    The commander..... the commander of what? Omnipresence? What do you know of value except a cocky attitue? Do you have any science background? If so, say what ? Why don't you get lost unless you have something of value to say? If so what is ti except being some cocky SOB. t

ISIS
51.51-0.9100(-1.74%)Nov 25 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.